OPK Opko Health, Inc. featured news, full reports, and detailed charts
Opko Health, Inc. (OPK) Wrap Up:
Opko Health, Inc., a specialty healthcare company, engages in the discovery, development, and commercialization of proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of ophthalmic disorders worldwide. It develops ophthalmic pharmaceuticals, as well as develops and sells ophthalmic diagnostic and imaging systems and instrumentation products. The company’s product candidates include bevasiranib, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration (Wet AMD), as well as in Phase I/II clinical trial for the treatment of diabetic retinopathy/diabetic macular edema. It a...www.opko.com
61 Employees
Founded in 2006
Opko Health, Inc. (OPK:AMEX)
LAST $2.07 USD
CHANGE TODAY +0.03 1.47%
VOLUME 93.9K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Opko Health, Inc. (OPK)
|
OPEN
$2.04
|
PREVIOUS CLOSE
$2.04
|
|
|
DAY HIGH
$2.09
|
DAY LOW
$2.04
|
|
|
52 WEEK HIGH
09/2/09 - $2.91
|
52 WEEK LOW
03/12/09 - $0.55
|
|
|
MARKET CAP
525.3M
|
AVERAGE VOLUME 3 mo
138.3K
|
|
|
DILUTED EPS TTM
$-0.15
|
SHARES OUTSTANDING
253.7M
|
|
|
OPK Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
OPK Top Compensated Officers
Dr. Phillip Frost M.D.
Chairman and Chief Executive Officer
Age: 72
Total Annual Compensation: $325.0K
Dr. Subbarao V. Uppaluri Ph.D., CFA
Chief Financial Officer and Senior Vice Presi...
Age: 59
Total Annual Compensation: $275.0K
Dr. Naveed K. Shams M.D., Ph.D.
Chief Medical Officer and Senior Vice Preside...
Age: 52
Total Annual Compensation: $259.1K
Mr. Adam Logal
Chief Accounting Officer, Executive Director ...
Age: 30
Total Annual Compensation: $112.6K
Dr. Jane H. Hsiao Ph.D.
Vice-Chairman and Chief Technical Officer
Age: 60
Total Annual Compensation: $300.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Opko Health, Inc. (OPK)
Opko Health, Inc. - Conference Presentation Call
11/16/2009
To provide a review of recent corporate developments
Opko Health, Inc. - Conference Presentation Call
09/16/2009
To provide a review of recent corporate developments
Opko Health Enters into Worldwide Exclusive License Agreement with Academia Sinica
07/20/2009
Opko Health Inc. has entered into a worldwide exclusive license agreement with Academia Sinica, Taiwan for a new technology to develop protein vaccines against influenza and other viral infections. Opko is forming a subsidiary in Taiwan to collaborate closely with Academia Sinica to develop the first product, a universal flu vaccine, to surmount the problem of the emergence of new strains against which vaccines produced with presently available technology do not provide satisfactory protection.
OPK Competitors
| Company | Last | Change |
| Carl-Zeiss Meditec | €10.85 EUR | +0.09 |
| Topcon Corporation | ¥490.00 JPY | -7.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | OPK | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 66.8x |
|
| Price/Book | 8.2x |
Not meaningful
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 57.0x |
|
|
OPK |
||
|
OPK transactions
| Type Date |
Target |
|
Merger/Acquisition
October 1, 2009 |
Pharma Genexx S.A. |
|
Private Placement
September 18, 2009 |
-- |
|
Merger/Acquisition
June 10, 2009 |
Quikbyte Software, Inc. |
More Recent News About Opko Health, Inc.
Would you like to leave a comment about Opko Health, Inc. OPK
Find out what social network information about Opko Health, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Opko Health, Inc. there is more great information available at Realpennies.com